A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

Phase 1 Recruiting 32 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and drug levels of Navlimetostat (BMS-986504) in participants with advanced solid tumors.

Timeline

Start: 2025-10-15
Primary completion: 2027-01-19
Completion: 2027-01-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986504	Unknown	—	—

A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications